Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness

Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis

(2020) Han Yang et al.   Drug Design Development and Therapy

The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction

(2020) Zanfina Ademi et al.   European Journal of Preventive Cardiology

Cost-Effectiveness of Alirocumab

(2019) Dhruv S. Kazi et al.   ANNALS OF INTERNAL MEDICINE

Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States

(2019) Thomas A. Gaziano et al.   AMERICAN HEART JOURNAL

The cost-effectiveness of omega-3 polyunsaturated fatty acids – The Australian healthcare perspective

(2019) Lan Gao et al.   European Journal of Internal Medicine

Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand

(2019) Khachen Kongpakwattana et al.   PHARMACOECONOMICS

Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort

(2019) Alexander Dressel et al.   VASCULAR PHARMACOLOGY

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease

(2019) Gregg C. Fonarow et al.   JAMA Cardiology

Transparency in Health Economic Modeling: Options, Issues and Potential Solutions

(2019) Eric Q. Wu et al.   PHARMACOECONOMICS

Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study

(2019) John K Lin et al.   Lancet Global Health

Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review

(2019) Samad Azari et al.   HEART FAILURE REVIEWS

Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia　― An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS) ―

(2018) Satoshi Kodera et al.   CIRCULATION JOURNAL

Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan

(2018) Satoshi Kodera et al.   CIRCULATION JOURNAL

Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial

(2018) Ziyad S. Almalki et al.   Heart Lung and Circulation

The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective

(2018) Radya Kumar et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol

(2018) Gregory A Nichols et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention

(2018) M. Arca et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Are PCSK9 Inhibitors Cost Effective?

(2018) Max J. Korman et al.   PHARMACOECONOMICS

The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension

(2018) Maria Cristina Peñaloza-Ramos et al.   VALUE IN HEALTH

Cost-effectiveness of interventions to control cardiovascular diseases and diabetes mellitus in South Asia: a systematic review

(2018) Kavita Singh et al.   BMJ Open

Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Gregory A Roth et al.   LANCET

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

A review of economic evaluations for beneficial health outcomes of micronutrient and long-chain omega-3 fatty acid supplementation

(2017) Michèle Jeanne Sadler   INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

(2017) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves

(2017) Ankur Pandya et al.   MEDICAL DECISION MAKING

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Utilidad de un policomprimido cardiovascular en el tratamiento de pacientes en prevención secundaria en España: un estudio de coste-efectividad

(2017) Vivencio Barrios et al.   REVISTA ESPANOLA DE CARDIOLOGIA

Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease

(2017) Dong-Churl Suh et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States

(2017) Glenn M. Davies et al.   JOURNAL OF MEDICAL ECONOMICS

Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

(2017) Peter P. Toth et al.   JOURNAL OF MEDICAL ECONOMICS

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers

(2017) Alejandro Arrieta et al.   JAMA Cardiology

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

(2017) Gregg C. Fonarow et al.   JAMA Cardiology

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease

(2016) Robert Klempfner et al.  

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

(2016) Shravanthi R. Gandra et al.   CLINICAL CARDIOLOGY

Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries

(2016) Ruth Webster et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease

(2016) Robert Klempfner et al.   Circulation-Cardiovascular Quality and Outcomes

Cost-effectiveness of adherence-enhancing interventions: a systematic review

(2016) Tzahit Simon-Tuval et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK

(2015) V. Becerra et al.   BMJ Open

The combined use of aspirin, a statin, and blood pressure–lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease

(2013) Melvin Lafeber et al.   AMERICAN HEART JOURNAL

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD

(2013) Simon Thom   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

(2013) D. Husereau et al.   BMJ-British Medical Journal

Comparative Cost-Effectiveness of Interventions to Improve Medication Adherence after Myocardial Infarction

(2012) Kouta Ito et al.   HEALTH SERVICES RESEARCH

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

(2012) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting

(2011) Martin R. Cowie et al.   EUROPEAN JOURNAL OF HEART FAILURE

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study

(2010) John Reckless et al.   VALUE IN HEALTH

Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland

(2009) Erkki J.O. Soini et al.   CURRENT MEDICAL RESEARCH AND OPINION